|
1
|
No authors listed, . Cancer statistics.
JAMA. 310:9822013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Garg K and Soslow RA: Endometrial
carcinoma in women aged 40 years and younger. Arch Pathol Lab Med.
138:335–342. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Clarke CL and Sutherland RL: Progestin
regulation of cellular proliferation. Endocr Rev. 11:266–301. 1990.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Nead KT, Sharp SJ, Thompson DJ, Painter
JN, Savage DB, Semple RK, Barker A; Australian National Endometrial
Cancer Study Group (ANECS); Perry JR, Attia J, et al: Evidence of a
causal association between insulinemia and endometrial cancer: A
mendelian randomization analysis. J Natl Cancer Inst. 107:pii:
djv178. 2015.PubMed/NCBI
|
|
5
|
Szablewski L: Diabetes mellitus:
Influences on cancer risk. Diabetes Metab Res Rev. 30:543–553.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
SGO Clinical Practice Endometrial Cancer
Working Group; Burke WM, Orr J, Leitao M, Salom E, Gehrig P,
Olawaiye AB, Brewer M, Boruta D, Villella J, et al: Endometrial
cancer: A review and current management strategies: Part I. Gynecol
Oncol. 134:385–392. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Mu N, Zhu Y, Wang Y, Zhang H and Xue F:
Insulin resistance: A significant risk factor of endometrial
cancer. Gynecol Oncol. 125:751–757. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Barone BB, Yeh HC, Snyder CF, Peairs KS,
Stein KB, Derr RL, Wolff AC and Brancati FL: Long-term all-cause
mortality in cancer patients with preexisting diabetes mellitus: A
systematic review and meta-analysis. JAMA. 300:2754–2764. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Friberg E, Orsini N, Mantzoros CS and Wolk
A: Diabetes mellitus and risk of endometrial cancer: A
meta-analysis. Diabetologia. 50:1365–1374. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Bowers LW, Rossi EL, O'Flanagan CH,
deGraffenried LA and Hursting SD: The role of the insulin/IGF
system in cancer: Lessons learned from clinical trials and the
energy balance-cancer link. Front Endocrinol (Lausanne).
6:772015.PubMed/NCBI
|
|
11
|
Gallagher EJ and LeRoith D: Obesity and
diabetes: The increased risk of cancer and cancer-related
mortality. Physiol Rev. 95:727–748. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Shao R, Li X, Feng Y, Lin JF and Billig H:
Direct effects of metformin in the endometrium: A hypothetical
mechanism for the treatment of women with PCOS and endometrial
carcinoma. J Exp Clin Cancer Res. 33:412014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Umene K, Banno K, Kisu I, Yanokura M,
Nogami Y, Tsuji K, Masuda K, Ueki A, Kobayashi Y, Yamagami W, et
al: New candidate therapeutic agents for endometrial cancer:
Potential for clinical practice (review). Oncol Rep. 29:855–860.
2013.PubMed/NCBI
|
|
14
|
Febbraro T, Lengyel E and Romero IL: Old
drug, new trick: Repurposing metformin for gynecologic cancers?
Gynecol Oncol. 135:614–621. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
He H, Ke R, Lin H, Ying Y, Liu D and Luo
Z: Metformin, an old drug, brings a new era to cancer therapy.
Cancer J. 21:70–74. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Viollet B, Guigas B, Garcia N Sanz,
Leclerc J, Foretz M and Andreelli F: Cellular and molecular
mechanisms of metformin: An overview. Clin Sci (Lond). 122:253–270.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Cantrell LA, Zhou C, Mendivil A, Malloy
KM, Gehrig PA and Bae-Jump VL: Metformin is a potent inhibitor of
endometrial cancer cell proliferation-implications for a novel
treatment strategy. Gynecol Oncol. 116:92–98. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Franciosi M, Lucisano G, Lapice E,
Strippoli GF, Pellegrini F and Nicolucci A: Metformin therapy and
risk of cancer in patients with type 2 diabetes: Systematic review.
PLoS One. 8:e715832013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Ko EM, Walter P, Jackson A, Clark L,
Franasiak J, Bolac C, Havrilesky LJ, Secord AA, Moore DT, Gehrig PA
and Bae-Jump V: Metformin is associated with improved survival in
endometrial cancer. Gynecol Oncol. 132:438–442. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Tabrizi AD, Melli MS, Foroughi M,
Ghojazadeh M and Bidadi S: Antiproliferative effect of metformin on
the endometrium-a clinical trial. Asian Pac J Cancer Prev.
15:10067–10070. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Takahashi A, Kimura F, Yamanaka A,
Takebayashi A, Kita N, Takahashi K and Murakami T: Metformin
impairs growth of endometrial cancer cells via cell cycle arrest
and concomitant autophagy and apoptosis. Cancer Cell Int.
14:532014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Sarfstein R, Friedman Y, Attias-Geva Z,
Fishman A, Bruchim I and Werner H: Metformin downregulates the
insulin/IGF-I signaling pathway and inhibits different uterine
serous carcinoma (USC) cells proliferation and migration in
p53-dependent or -independent manners. PLoS One. 8:e615372013.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wu B, Li S, Sheng L, Zhu J, Gu L, Shen H,
La D, Hambly BD, Bao S and Di W: Metformin inhibits the development
and metastasis of ovarian cancer. Oncol Rep. 28:903–908.
2012.PubMed/NCBI
|
|
24
|
Chou CC, Lee KH, Lai IL, Wang D, Mo X,
Kulp SK, Shapiro CL and Chen CS: AMPK reverses the mesenchymal
phenotype of cancer cells by targeting the Akt-MDM2-Foxo3a
signaling axis. Cancer Res. 74:4783–4795. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Bao B, Azmi AS, Ali S, Zaiem F and Sarkar
FH: Metformin may function as anti-cancer agent via targeting
cancer stem cells: The potential biological significance of
tumor-associated miRNAs in breast and pancreatic cancers. Ann
Transl Med. 2:592014.PubMed/NCBI
|
|
26
|
Lambe M, Wigertz A, Garmo H, Walldius G,
Jungner I and Hammar N: Impaired glucose metabolism and diabetes
and the risk of breast, endometrial, and ovarian cancer. Cancer
Causes Control. 22:1163–1171. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Moran LJ, Hutchison SK, Norman RJ and
Teede HJ: Lifestyle changes in women with polycystic ovary
syndrome. Cochrane Database Syst Rev. CD0075062011.
|
|
28
|
Sinnett-Smith J, Kisfalvi K, Kui R and
Rozengurt E: Metformin inhibition of mTORC1 activation, DNA
synthesis and proliferation in pancreatic cancer cells: Dependence
on glucose concentration and role of AMPK. Biochem Biophys Res
Commun. 430:352–357. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Menendez JA, Oliveras-Ferraros C, Cufí S,
Corominas-Faja B, Joven J, Martin-Castillo B and Vazquez-Martin A:
Metformin is synthetically lethal with glucose withdrawal in cancer
cells. Cell Cycle. 11:2782–2792. 2012. View
Article : Google Scholar : PubMed/NCBI
|
|
30
|
Zhuang Y, Chan DK, Haugrud AB and
Miskimins WK: Mechanisms by which low glucose enhances the
cytotoxicity of metformin to cancer cells both in vitro and in
vivo. PLoS One. 9:e1084442014. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Kato H, Sekine Y, Furuya Y, Miyazawa Y,
Koike H and Suzuki K: Metformin inhibits the proliferation of human
prostate cancer PC-3 cells via the downregulation of insulin-like
growth factor 1 receptor. Biochem Biophys Res Commun. 461:115–121.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Chen X, Hu C, Zhang W, Shen Y, Wang J, Hu
F and Yu P: Metformin inhibits the proliferation, metastasis, and
cancer stem-like sphere formation in osteosarcoma MG63 cells in
vitro. Tumour Biol. 36:9873–9883. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Han J, Zhang L, Guo H, Wysham WZ, Roque
DR, Willson AK, Sheng X, Zhou C and Bae-Jump VL: Glucose promotes
cell proliferation, glucose uptake and invasion in endometrial
cancer cells via AMPK/mTOR/S6 and MAPK signaling. Gynecol Oncol.
138:668–675. 2015. View Article : Google Scholar : PubMed/NCBI
|
